[SCHEDULE 13G/A] Autolus Therapeutics plc SEC Filing

Rhea-AI Filing Summary

Wellington Management filed an amended Schedule 13G reporting its position in Autolus Therapeutics plc (AUTL) common stock. The filing lists three related Wellington entities organized in MASSACHUSETTS and DELAWARE that collectively report 0.0% beneficial ownership of the class and 0 shares of sole voting or dispositive power. The securities are owned of record by clients of Wellington investment advisers and are held in the ordinary course of business, with no client reported as having more than 5% of the class. The cover lists the issuer address in London and the event date 09/30/2025; the filing is signed on 10/07/2025 by a Wellington regulatory analyst.

Positive

• Clear disclosure of entity structure and reporting chain among Wellington affiliates
• Certifies ordinary-course holdings and explicitly states no client holds more than 5% of the class
• Timely amendment with event date 09/30/2025 and signature dated 10/07/2025

Negative

• No beneficial ownership reported (0.0%), indicating no economic or voting exposure from these filers

Insights

Institutional Ownership Analyst

TL;DR: Wellington reports no beneficial stake in AUTL as of 09/30/2025.

The filing identifies three Wellington-related entities and multiple Wellington investment advisers as record owners for client accounts, but shows an aggregate beneficial ownership of 0.0% and zero shares of sole or shared voting and dispositive power. This indicates Wellington does not hold a reportable economic or voting position in the common stock class.

The position is described as held in the ordinary course of business with no client exceeding 5% of the class. Investors looking for changes in ownership should note the 09/30/2025 event date and the 10/07/2025 signature; subsequent filings would disclose any new positions.

Corporate Governance Specialist

TL;DR: This Schedule 13G/A confirms non-activist, non-controlling record holdings by Wellington-affiliated advisers.

The statement certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing control. The filing lists parent/subsidiary relationships among Wellington entities, clarifying reporting chain and the advisers exercising record ownership for clients.

Key governance watchers should note there is no group formation or >5% ownership disclosed, so there are no reported voting blocs or control-related disclosures tied to these Wellington entities at the stated date.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Autolus Therapeutics plc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

G06630100

(CUSIP Number)

09/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G06630100

1

Names of Reporting Persons

Wellington Management Group LLP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. G06630100

1

Names of Reporting Persons

Wellington Group Holdings LLP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. G06630100

1

Names of Reporting Persons

Wellington Investment Advisors Holdings LLP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Autolus Therapeutics plc
(b)	Address of issuer's principal executive offices: The Mediaworks, 191 Wood Lane, London W12 7FP
Item 2.
(a)	Name of person filing: Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP
(b)	Address or principal business office or, if none, residence: c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210
(c)	Citizenship: Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: G06630100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the responses to Item 9 on the attached cover pages.
(b)	Percent of class: 0.00 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: See the responses to Item 6 on the attached cover pages.
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: See the responses to Item 8 on the attached cover pages.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Wellington Group Holdings LLP - HC Wellington Investment Advisors LLP - HC Wellington Management Global Holdings, Ltd. - HC One or more of the following investment advisers (the "Wellington Investment Advisers"): Wellington Management Company LLP - IA Wellington Management Canada LLC - IA Wellington Management Singapore Pte Ltd - IA Wellington Management Hong Kong Ltd - IA Wellington Management International Ltd - IA Wellington Management Japan Pte Ltd - IA Wellington Management Australia Pty Ltd - IA The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Wellington Management Group LLP

Signature:	Taisia Lowe
Name/Title:	Regulatory Analyst
Date:	10/07/2025

Wellington Group Holdings LLP

Signature:	Taisia Lowe
Name/Title:	Regulatory Analyst
Date:	10/07/2025

Wellington Investment Advisors Holdings LLP

Signature:	Taisia Lowe
Name/Title:	Regulatory Analyst
Date:	10/07/2025

FAQ

What does the Schedule 13G/A filed by Wellington mean for AUTL (AUTL) ownership?

The filing shows Wellington-related entities report an aggregate beneficial ownership of 0.0% in AUTL common stock, meaning they do not hold a reportable economic or voting stake in the class.

Who filed the Schedule 13G/A for Autolus Therapeutics (AUTL)?

The filing was made by Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP, with a principal address c/o Wellington Management Company LLP, 280 Congress Street, Boston, MA.

What date does the filing cover and when was it signed?

The event date requiring the filing is 09/30/2025 and the signature date on the amendment is 10/07/2025.

Does Wellington claim any intent to influence control of Autolus Therapeutics (AUTL)?

No; the certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.

Are any Wellington clients reported as owning more than 5% of AUTL?

No; the filing states no client is known to have the right or power with respect to more than 5% of the class.